Download PDF
Aktuelle Neurologie 2015; 42(02): 97-101
DOI: 10.1055/s-0034-1387577
Debatte: Pro & Kontra
© Georg Thieme Verlag KG Stuttgart · New York

Multiple Sklerose-Therapie so früh wie möglich – Kontra

Early Treatment of Multiple Sclerosis – Contra
A. Steinbrecher
Klinik für Neurologie, HELIOS Klinikum Erfurt
› Author Affiliations
Further Information

Publication History

Publication Date:
16 March 2015 (online)

Also available at
    Permissions and Reprints

Einleitung

Die multiple Sklerose (MS) ist die zweithäufigste Ursache neurologischer Behinderung junger Menschen und eine der teuersten chronischen Erkrankungen. Etwa 85 % der Betroffenen haben eine schubförmig-remittierende MS (RRMS), bei der Schübe mit mehr oder weniger vollständiger Remission den klinischen Beginn der Erkrankung charakterisieren. Neurologische Defizite und Behinderung werden üblicherweise mittels der Expanded Disability Status Scale (EDSS) gemessen.

 

  • Literatur

  • 1 Coles AJ, Cox A, Le Page E et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006; 253: 98-108
    CrossrefPubMedGoogle Scholar
  • 2 Comi G. Clinically isolated syndrome: the rationale for early treatment. Nat Clin Pract Neurol 2008; 4: 234-235
    PubMedGoogle Scholar
  • 3 Tintore M, Rovira A, Rio J et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 2006; 67: 968-972
    CrossrefPubMedGoogle Scholar
  • 4 Fisniku LK, Brex PA, Altmann DR et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008; 131: 808-817
    CrossrefPubMedGoogle Scholar
  • 5 Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol 2008; 65: 727-732
    PubMedGoogle Scholar
  • 6 Swanton JK, Fernando K, Miller D. Early prognosis of multiple sclerosis. In: Goodin DS, Hrsg. Multiple sclerosis and related disorders. Oxford: Elsevier; 2014: 371-391
    CrossrefGoogle Scholar
  • 7 Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003; 126: 770-782
    CrossrefPubMedGoogle Scholar
  • 8 Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006; 129: 606-616
    CrossrefPubMedGoogle Scholar
  • 9 Bergamaschi R, Montomoli C, Candeloro E et al. Disability and mortality in a cohort of multiple sclerosis patients: a reappraisal. Neuroepidemiology 2005; 25: 15-18
    CrossrefPubMedGoogle Scholar
  • 10 Kremenchutzky M, Rice GP, Baskerville J et al. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 2006; 129: 584-594
    CrossrefPubMedGoogle Scholar
  • 11 Scalfari A, Neuhaus A, Daumer M et al. Onset of secondary progressive phase and long-term evolution of multiple sclerosis. J Neurol Neurosurg Psychiatry 2014; 85: 67-75
    CrossrefPubMedGoogle Scholar
  • 12 Scalfari A, Neuhaus A, Daumer M et al. Early relapses, onset of progression, and late outcome in multiple sclerosis. JAMA Neurol 2013; 70: 214-222
    CrossrefPubMedGoogle Scholar
  • 13 Scalfari A, Neuhaus A, Degenhardt A et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 2010; 133: 1914-1929
    CrossrefPubMedGoogle Scholar
  • 14 Filippini G, Del Giovane C, Vacchi L et al. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochrane Database oSyst Rev 2013; 6 CD008933
    PubMedGoogle Scholar
  • 15 Coles AJ, Fox E, Vladic A et al. Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 2012; 78: 1069-1078
    CrossrefPubMedGoogle Scholar
  • 16 Cohen JA, Coles AJ, Arnold DL et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012; 380: 1819-1828
    CrossrefPubMedGoogle Scholar
  • 17 Kappos L, Polman CH, Freedman MS et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67: 1242-1249
    CrossrefPubMedGoogle Scholar
  • 18 Kappos L, Freedman MS, Polman CH et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. The Lancet Neurology 2009; 8: 987-997
    CrossrefPubMedGoogle Scholar
  • 19 Edan G, Kappos L, Montalban X et al. Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. J Neurol Neurosurg Psychiatry 2013; DOI: 10.1136/jnnp-2013-306222.
    PubMedGoogle Scholar
  • 20 Jacobs LD, Beck RW, Simon JH et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343: 898-904
    CrossrefPubMedGoogle Scholar
  • 21 Kinkel RP, Kollman C, O’Connor P et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006; 66: 678-684
    CrossrefPubMedGoogle Scholar
  • 22 Kinkel RP, Dontchev M, Kollman C et al. Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance. Arch Neurol 2012; 69: 183-190
    CrossrefPubMedGoogle Scholar
  • 23 Comi G, Filippi M, Barkhof F et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576-1582
    CrossrefPubMedGoogle Scholar
  • 24 OWIMS Study Group. Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group. Neurology 1999; 53: 679-686
    CrossrefPubMedGoogle Scholar
  • 25 Comi G, De Stefano N, Freedman MS et al. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol 2012; 11: 33-41
    CrossrefPubMedGoogle Scholar
  • 26 Freedman MS, De Stefano N, Barkhof F et al. Patient subgroup analyses of the treatment effect of subcutaneous interferon beta-1a on development of multiple sclerosis in the randomized controlled REFLEX study. J Neurol 2014; 261: 490-499
    CrossrefPubMedGoogle Scholar
  • 27 Comi G, Martinelli V, Rodegher M et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374: 1503-1511
    CrossrefPubMedGoogle Scholar
  • 28 Comi G, Martinelli V, Rodegher M et al. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Mult Scler 2013; 19: 1074-1083
    CrossrefPubMedGoogle Scholar
  • 29 Goodin DS, Reder AT, Ebers GC et al. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNbeta-1b trial. Neurology 2012; 78: 1315-1322
    CrossrefPubMedGoogle Scholar
  • 30 Trojano M, Pellegrini F, Fuiani A et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol 2007; 61: 300-306
    CrossrefPubMedGoogle Scholar
  • 31 Conway DS, Miller DM, O’Brien RG et al. Long-term benefit of multiple sclerosis treatment: an investigation using a novel data collection technique. Mult Scler 2012; 18: 1617-1624
    CrossrefPubMedGoogle Scholar
  • 32 Shirani A, Zhao Y, Karim ME et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 2012; 308: 247-256
    CrossrefPubMedGoogle Scholar
  • 33 Tedeholm H, Lycke J, Skoog B et al. Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs. Mult Scler 2013; 19: 765-774
    CrossrefPubMedGoogle Scholar
  • 34 De Stefano N, Narayanan S, Francis GS et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001; 58: 65-70
    CrossrefPubMedGoogle Scholar
  • 35 DeLuca GC, Williams K, Evangelou N et al. The contribution of demyelination to axonal loss in multiple sclerosis. Brain 2006; 129: 1507-1516
    CrossrefPubMedGoogle Scholar
  • 36 Kuhlmann T, Lingfeld G, Bitsch A et al. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002; 125: 2202-2212
    CrossrefPubMedGoogle Scholar
  • 37 Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder?. Annu Revi Neurosci 2008; 31: 247-269
    PubMedGoogle Scholar
  • 38 Bermel RA, You X, Foulds P et al. Predictors of long-term outcome in multiple sclerosis patients treated with interferon beta. Ann Neurol 2013; 73: 95-103
    PubMedGoogle Scholar
  • 39 Hawton A, Shearer J, Goodwin E et al. Squinting through layers of fog: assessing the cost effectiveness of treatments for multiple sclerosis. Appl Health Econ Health Policy 2013; 11: 331-341
    CrossrefPubMedGoogle Scholar
  • 40 Fredrikson S, McLeod E, Henry N et al. A cost-effectiveness analysis of subcutaneous interferon beta-1a 44mcg 3-times a week vs no treatment for patients with clinically isolated syndrome in Sweden. J Med Econ 2013; 16: 756-762
    CrossrefPubMedGoogle Scholar
  • 41 Noyes K, Bajorska A, Chappel A et al. Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study. Neurology 2011; 77: 355-363
    CrossrefPubMedGoogle Scholar